Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes
Journal of Pediatric Endocrinology and Metabolism · 26.03.2026 · 39 (3) · 258-264
DOI: 10.1515/jpem-2025-0733 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 26.01.2026. Verfasst von Özge Köprülü und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Dr. Behçet Uz Children's Education and Research Hospital, Izmir, Türkiye. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Quality of Life, Hypoglycemia, Fear. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
This study aimed to evaluate changes in fear of hypoglycemia (FOH) and quality of life (QoL) following at least six months of continuous glucose monitoring (CGM) use in the same cohort with type 1 diabetes mellitus (T1DM).
Methods
This was a prospective, observational study including first-time CGM users. Auxologic, laboratory, and CGM data was collected. All participants were asked to complete the validated Turkish versions of the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module for both children and parents; the quality of life for youth scale for adolescents; children’s hypoglycemia index (CHI).
Results
When pre- and post-CGM scores were compared, the mean total CHI score significantly decreased (p=0.018). Among the subscales, significant reductions were also observed in the “specific situations” (p=0.044) and “behavior scales” (p=0.025) subscales, whereas the “general fears” did not show a significant change (p=0.396). In PedsQL forms, there were no statistically significant differences between pre- and post-CGM total or subscale scores. CGM metrics were also compared between participants who showed improvement in FOH and/or QoL and those who did not. Participants with improvement in FOH had significantly higher sensor active use percentages compared to those without improvement (98.95 vs. 93.0 %, p=0.039).
Conclusions
This study’s ability to assess pre- and post-CGM outcomes in the same patients highlights its clinical significance. Our findings suggest that using CGM in children and adolescents with T1DM is associated with a reduction in FOH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, Dr. Behçet Uz Children's Education and Research Hospital, Izmir, Türkiye.
- Department of Pediatrics, İzmir Faculty of Medicine, University of Health Sciences, Izmir, Türkiye.
ORCID-Profile: Özge Köprülü, Murat Çağlar Karataş, Sevgi Akbel, Fatma Yavuzyılmaz Şimşek, İbrahim Mert Erbaş, Özlem Nalbantoğlu, Hüseyin Anıl Korkmaz, Behzat Özkan
Zitieren
APA
Köprülü, Ö., Karataş, M. Ç., Akbel, S., Şimşek, F. Y., Erbaş, İ. M., Nalbantoğlu, Ö., Korkmaz, H. A., & Özkan, B. (2026). Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes. Journal of Pediatric Endocrinology and Metabolism, 39(3), 258-264. https://doi.org/10.1515/jpem-2025-0733
Vancouver
Köprülü Ö, Karataş MÇ, Akbel S, Şimşek FY, Erbaş İM, Nalbantoğlu Ö, et al. Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes. Journal of Pediatric Endocrinology and Metabolism. 2026;39(3):258-264. doi:10.1515/jpem-2025-0733
BibTeX
@article{Kprl2026,
author = {Köprülü, Özge and Karataş, Murat Çağlar and Akbel, Sevgi and Şimşek, Fatma Yavuzyılmaz and Erbaş, İbrahim Mert and Nalbantoğlu, Özlem and Korkmaz, Hüseyin Anıl and Özkan, Behzat},
title = {Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2026},
volume = {39},
number = {3},
pages = {258--264},
doi = {10.1515/jpem-2025-0733}
}
EUVIMED